NCT05076396 - PM14 Administered Intravenously to Patients with Advanced Solid Tumors | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

August 13, 2025

Study Completion Date

August 13, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

PM14

PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.

Trial Locations (9)

28007

RECRUITING

Hospital General Universitario Gregorio Marañón, Madrid

28027

RECRUITING

Clinica Universidad de Navarra, Madrid

28040

RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28050

RECRUITING

Hospital Universitario Madrid Sanchinarro, Madrid

77030

RECRUITING

MD Anderson Cancer Center, Houston

94805

RECRUITING

Gustave Roussy, Villejuif

02114

RECRUITING

Massachusetts General Hospital, Boston

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona